Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Ontario Teachers Pension Plan Board

Ontario Teachers Pension Plan Board decreased its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 61.0% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 54,945 shares of the biopharmaceutical company's stock after selling 86,115 shares during the quarter. Ontario Teachers Pension Plan Board's holdings in Bristol-Myers Squibb were worth $2,843,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of BMY. Bessemer Group Inc. increased its holdings in shares of Bristol-Myers Squibb by 16.3% in the 1st quarter. Bessemer Group Inc. now owns 159,066 shares of the biopharmaceutical company's stock worth $8,625,000 after buying an additional 22,286 shares during the last quarter. Lake Street Advisors Group LLC increased its holdings in shares of Bristol-Myers Squibb by 54.7% in the 1st quarter. Lake Street Advisors Group LLC now owns 13,530 shares of the biopharmaceutical company's stock worth $734,000 after buying an additional 4,784 shares during the last quarter. Ossiam increased its holdings in shares of Bristol-Myers Squibb by 31.7% in the 1st quarter. Ossiam now owns 88,183 shares of the biopharmaceutical company's stock worth $4,782,000 after buying an additional 21,234 shares during the last quarter. Payden & Rygel Investment Group bought a new stake in shares of Bristol-Myers Squibb in the 1st quarter worth about $206,000. Finally, EntryPoint Capital LLC increased its holdings in shares of Bristol-Myers Squibb by 113.0% in the 1st quarter. EntryPoint Capital LLC now owns 3,501 shares of the biopharmaceutical company's stock worth $190,000 after buying an additional 1,857 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Insider Transactions at Bristol-Myers Squibb

In other news, EVP Samit Hirawat acquired 1,830 shares of the business's stock in a transaction that occurred on Friday, November 1st. The stock was purchased at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the transaction, the executive vice president now owns 62,109 shares in the company, valued at approximately $3,395,499.03. This trade represents a 3.04 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Phil M. Holzer sold 700 shares of the firm's stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $55.62, for a total transaction of $38,934.00. Following the sale, the senior vice president now owns 11,760 shares of the company's stock, valued at approximately $654,091.20. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.09% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Daiwa Capital Markets upgraded shares of Bristol-Myers Squibb from a "neutral" rating to an "outperform" rating in a report on Wednesday, November 13th. Barclays boosted their price objective on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an "underweight" rating in a research report on Monday, October 7th. Daiwa America raised shares of Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, November 13th. Sanford C. Bernstein started coverage on shares of Bristol-Myers Squibb in a research report on Thursday, October 17th. They issued a "market perform" rating and a $56.00 price objective for the company. Finally, Citigroup upped their price target on shares of Bristol-Myers Squibb from $55.00 to $60.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, two have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, Bristol-Myers Squibb currently has an average rating of "Hold" and a consensus price target of $54.07.

Bristol-Myers Squibb Stock Performance

NYSE BMY traded down $0.35 during mid-day trading on Wednesday, reaching $57.88. 10,594,627 shares of the stock were exchanged, compared to its average volume of 14,426,227. The business's 50 day moving average is $53.08 and its 200-day moving average is $47.47. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $61.08. The company has a market capitalization of $117.39 billion, a P/E ratio of -16.21, a P/E/G ratio of 15.08 and a beta of 0.44. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.31. The business had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company's revenue was up 8.4% compared to the same quarter last year. During the same period last year, the firm posted $2.00 earnings per share. On average, equities research analysts forecast that Bristol-Myers Squibb will post 0.93 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Friday, October 4th were issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 4.15%. The ex-dividend date was Friday, October 4th. Bristol-Myers Squibb's payout ratio is -66.85%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.